Novo Nordisk A/s

Lotte Bjerre Knudsen

Jesper F Lau

Johan Selmer

Min Teng

Jun Feng

Peter Madsen

Yufeng Hong

Christian Klarner Sams

Vlad Edward Gregor

Michael Bruno Plewe

Paw Bloch

Lars Naerum

Anthony Lai Ling

Shenghua Shi

Kristian Tage Hansen

Javier Gonzalez

Michael David Johnson

Atsuo Kuki

Ulla Grove Sidelmann

Kirsten Raun

Dan Kiel

Michael Paolo Bastner Sandrini

Pia Von Voss

Kimberly Ann Teston

Nikolaj Kulahin Roed

Adam Paul Chambers

Anna Secher

Jim McGuire

Jim Mcguire

Kjell Malmlöf

Charlotte Christine Thim Hansen

Sarah Friedrich

The invention relates to a construct comprising a compound targeting areas in the brain involved in the regulation of body weight and an allosteric ligand to a receptor located in the blood-brain barrier (BBB). The invention also relates to compositions and uses of such construct, for example in the prevention or treatment of overweight and obesity. Preferred compounds for regulation of body weight include GLP-1 receptor agonists (GLP-1RA), and preferred receptors located in the BBB include the transferrin receptor (TfR). Exemplary fusions and conjugates of GLP-1 RA's and anti TfR-Fab's exhibit an increased binding to brain regions expressing the GLP-1 receptor as compared to fusions or conjugates with inactive control Fab's, in particular in brain areas protected by the BBB. In vivo mice studies confirm increased reduction in food intake as well as weight loss for the active construct compared to the inactive one.

Compounds for treatment of obesity

Use of medicament for life saving treatment of critically ill patients and method of treatment. The medicament comprises a GLP-1 compound which effectively controls the blood glucose level.

Use of GLP-1 compound for treatment of critically ill patients

Methods and uses for treatment of dyslipidemia comprising administration of a GLP-1 compound and another antidyslipidemic drug.

Combined use of a GLP-1 compound and another drug for treating dyslipidemia

Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof are disclosed. The compounds act to antagonize the action of the glucagon peptide hormone.

Glucagon antagonists/inverse agonists

Growing community of inventors

Valby, Denmark

Lotte Bjerre Knudsen